Another round of opioid settlement funding is headed to Maryland. More than $13 million from seven generic opioid manufacturers will bolster efforts to expand treatment, recovery, prevention, and harm reduction services.
According to a Baltimore Banner article, Maryland will receive more than $13 million from seven generic opioid manufacturers as part of a new nationwide settlement. The funding will support treatment, recovery, and prevention efforts as the state continues to address the opioid epidemic, which claimed more than 1,400 lives in 2025.
The settlements involve Alvogen, Amneal, Apotex, Hikma, Mylan, Sun, and Zydus, manufacturers of generic opioid medications including oxycodone, hydrocodone, and fentanyl patches. In addition to the financial payments, the agreements impose new business restrictions, including bans on marketing opioids to prescribers and patients, prohibiting sales incentives tied to opioid volume, and requiring companies to monitor and report suspicious opioid orders.
The latest agreement builds on Maryland’s broader opioid litigation efforts, which have already secured hundreds of millions of dollars from drug manufacturers and distributors. Earlier this year, the state launched a public dashboard tracking how settlement dollars are being distributed and spent. As previously covered by MACo, the dashboard was created under legislation passed during the 2025 General Assembly session (HB 798/SB 589), which directed the Office and the Maryland Department of Health to establish a public-facing tracking system for opioid settlement funding. MACo worked with the bill sponsors and committees to address duplicative reporting requirements and supported the legislation with those amendments.
From the Baltimore Banner article:
At that time, Maryland was expected to receive more than $747 million over the next 15 years, and nearly $170 million had been made available to counties and cities across the state.
Local governments, working closely with local health departments and community partners, play a critical role in addressing the opioid crisis. As front-line responders, they are using opioid settlement funds to expand prevention, treatment, recovery, harm reduction, and public safety initiatives tailored to local needs.
